Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized Phase 2 study of OMS210 in diarrhoea predominant irritable bowel syndrome
2010-019343-20Phase 2Completed
- Sponsor
- Lotus Pharmaceutical
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ramosetron in irritable bowel syndrome (IBS) (3 arms), sponsored by Lotus Pharmaceutical. Primary endpoint: Primary responder rate at 4 weeks. Started Apr 2010; status: completed.
02
Drugs
ramosetron
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2010-019343-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019343-20.